Robert H Bates

发表

Prioritizing multiple therapeutic targets in parallel using automated DNA-encoded library screening

Gang Yao, Bing Xia, Jing Chai, 2017, Nature Communications.

Testing Tuberculosis Drug Efficacy in a Zebrafish High-Throughput Translational Medicine Screen

Robert H Bates, T. Hankemeier, A. Ordas, 2014, Antimicrobial Agents and Chemotherapy.

Fueling Open-Source Drug Discovery: 177 Small-Molecule Leads against Tuberculosis

Alfonso Mendoza, Benigno Crespo, David Barros, 2013, ChemMedChem.

Screening of a Novel Fragment Library with Functional Complexity against Mycobacterium tuberculosis InhA

Robert H Bates, David Barros, C. Chung, 2018, ChemMedChem.

Kinetics of Model Reactions for Interfacial Polymerization

Robert H Bates, A. Padías, H. K. Hall, 2012 .

Release of 50 new, drug-like compounds and their computational target predictions for open source anti-tubercular drug discovery

John P. Overington, James R. Brown, Robert H Bates, 2015, PloS one.

The Tuberculosis Drug Accelerator at year 10: what have we learned?

H. M. Petrassi, Christopher B. Cooper, Robert H Bates, 2021, Nature Medicine.

throughput translational medicine screen 2

Robert H Bates, T. Hankemeier, A. Ordas, 2014 .

An approach to the stereoselective synthesis of enantiopure dihydropyrroles and aziridines from a common sulfinyl-sulfinamide intermediate.

Robert H Bates, Ignacio Colomer, A. Viso, 2012, The Journal of organic chemistry.

Lysyl-tRNA synthetase, a target for urgently needed M. tuberculosis drugs

Robert H Bates, L. Stojanovski, K. Read, 2022, Nature Communications.

Improved BM212 MmpL3 Inhibitor Analogue Shows Efficacy in Acute Murine Model of Tuberculosis Infection

Robert H Bates, M. Botta, V. L. La Rosa, 2013, PloS one.

GSK2556286 Is a Novel Antitubercular Drug Candidate Effective In Vivo with the Potential To Shorten Tuberculosis Treatment

Robert H Bates, N. Fotouhi, G. Besra, 2022, bioRxiv.

Exploring the SAR of the β-Ketoacyl-ACP Synthase Inhibitor GSK3011724A and Optimization around a Genotoxic Metabolite.

Robert H Bates, Fraser Cunningham, C. Chung, 2020, ACS infectious diseases.

Sulfoxide-directed enantioselective synthesis of functionalized tetrahydropyridines.

Robert H Bates, A. Viso, C. Simal, 2013, Organic letters.

Differential characterization using readily accessible NMR experiments of novel N- and O-alkylated quinolin-4-ol, 1,5-naphthyridin-4-ol and quinazolin-4-ol derivatives with antimycobacterial activity.

Robert H Bates, Fraser Cunningham, P. Van der Veken, 2017, European journal of medicinal chemistry.

Novel Pyrazole-Containing Compounds Active against Mycobacterium tuberculosis.

Robert H Bates, T. Ioerger, E. Rubin, 2019, ACS medicinal chemistry letters.

Identification of β-Lactams Active against Mycobacterium tuberculosis by a Consortium of Pharmaceutical Companies and Academic Institutions

Robert H Bates, M. Vieth, P. Hipskind, 2022, ACS infectious diseases.

Pharmacokinetics of β-Lactam Antibiotics: Clues from the Past To Help Discover Long-Acting Oral Drugs in the Future

Paul W Smith, Robert H Bates, K. Read, 2018, ACS infectious diseases.

Synthesis of Enantiopure 3-Hydroxypiperidines from Sulfinyl Dienyl Amines by Diastereoselective Intramolecular Cyclization and [2,3]-Sigmatropic Rearrangement.

Robert H Bates, A. Viso, C. Simal, 2015, The Journal of organic chemistry.

Pharmaceutical salt of BM635 with improved bioavailability

Robert H Bates, Lluís Ballell, G. Poce, 2017, European Journal of Pharmaceutical Sciences.

Stereoselective syntheses of the C(1)-C(9) fragment of amphidinolide C.

Robert H Bates, W. Roush, J. Shotwell, 2008, Organic letters.

Identification of KasA as the cellular target of an anti-tubercular scaffold

Robert H Bates, N. Loman, G. Drewes, 2016, Nature Communications.

Searching for New Leads for Tuberculosis: Design, Synthesis, and Biological Evaluation of Novel 2-Quinolin-4-yloxyacetamides.

Robert H Bates, Fraser Cunningham, P. Van der Veken, 2016, Journal of medicinal chemistry.

Optimization of hydantoins as potent antimycobacterial decaprenylphosphoryl-β-D-ribose oxidase (DprE1) inhibitors.

Robert H Bates, Fraser Cunningham, P. Van der Veken, 2020, Journal of medicinal chemistry.

Identification and Profiling of Hydantoins-A Novel Class of Potent Antimycobacterial DprE1 Inhibitors.

Christophe M. L. Vande Velde, Robert H Bates, Fraser Cunningham, 2018, Journal of medicinal chemistry.

Novel insight into the reaction of nitro, nitroso and hydroxylamino benzothiazinones and of benzoxacinones with Mycobacterium tuberculosis DprE1

Robert H Bates, G. Besra, C. Chung, 2018, Scientific Reports.

Optimization of TAM16, a Benzofuran That Inhibits the Thioesterase Activity of Pks13; Evaluation toward a Preclinical Candidate for a Novel Antituberculosis Clinical Target

Robert H Bates, L. Stojanovski, K. Read, 2021, Journal of medicinal chemistry.

Pharmacokinetics of β-Lactam Antibiotics

Robert H Bates, K. Read, F. Zuccotto, 1983 .

Prioritizing multiple therapeutic targets in parallel using automated DNA-encoded library screening

Robert H Bates, G. Besra, J. Lelièvre, 2017, Nature Communications.

University of Birmingham Identification of KasA as the cellular target of an anti-tubercular scaffold

Robert H Bates, N. Loman, G. Drewes, 2016 .